A Pilot Study to Evaluate PureWick for Nocturia

Sponsor
Weill Medical College of Cornell University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05090722
Collaborator
Becton, Dickinson and Company (Industry)
40
1
1
8.5
4.7

Study Details

Study Description

Brief Summary

This is a single-center prospective pilot study of PureWick used as a management for nocturia and reduction of nighttime falls associated with going to the bathroom. Subjects are followed up to 3 months after the intervention. As a pilot study, it is expected that a 3-month follow-up will adequately capture urinary and sleep outcomes data and any adverse events related or unrelated to the study device.

Condition or Disease Intervention/Treatment Phase
  • Device: PureWick System
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Pilot Study to Evaluate PureWick for Nocturia
Actual Study Start Date :
Dec 16, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: The PureWick Urine Collection System

The PureWick Urine Collection System is intended for non-invasive urine output management. It pulls urine through tubing that is connected to a collection canister for proper disposal. It is designed to be used by patients, caregivers, or healthcare professionals in both home environments and professional care facilities.

Device: PureWick System
The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
Other Names:
  • PureWick Urine Collection System device
  • PWF030F
  • Outcome Measures

    Primary Outcome Measures

    1. The proportion of patients at 3 months who have a demonstrated 50% or greater reduction in the number of nocturia episodes/night [3 months]

      The proportion of patients at 3 months who have a demonstrated 50% or greater reduction in the number of nocturia episodes/night will be calculated via binomial proportions and an exact (Clopper-Pearson) 95% confidence interval will be computed to assess the precision of the obtained estimate.

    2. Change in average number of nocturnal voids at baseline and at 3 months [At baseline and 3 months]

      The paired t-test or Wilcoxon signed-rank test will be used, as appropriate, to compare the average number of nocturnal voids between baseline and at 3 months.

    3. Change of scores on the N-QoL at baseline and at 3-months [At baseline and 3 months]

      N-QoL (Nocturia quality of life) score is determined by the n-qol short form. The ICIQ-Nqol is a patient-completed questionnaire evaluating quality of life (QoL) in patients with nocturia for use in research and clinical practice across the world. The ICIQ-Nqol is the N-QoL adapted for use within the ICIQ structure and provides a detailed and robust measure to assess the impact of nocturia on quality of life with particular reference to the effects on patient' lives of Nocturia and can be used as an outcome measure to assess impact of different treatment modalities. 0-52 overall score with greater values indicating increased impact on quality of life Bother scale not incorporated into overall score but indicate impact of symptoms overall for the patient. Similar analyses to paired t-test or Wilcoxon signed-rank test will be performed to compare scores on the N-QoL, an self-reported sleep quality between baseline and at 3-months.

    Secondary Outcome Measures

    1. Change in the incidence of urinary tract infection (UTI) at baseline and 3 months [At baseline and 3 months]

      McNemar's chi-square test will be used to compare the incidence of UTI between baseline and at 3 months.

    2. Change in the incidence of pressure ulcers/skin breakdown at baseline and 3 months [At baseline and 3 months]

      McNemar's chi-square test will be used to compare pressure ulcers/skin breakdown between baseline and at 3 months.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Women aged 50 years or older.

    • Experiences 2 or more voids per night as assessed on a 3-day bladder diary.

    Exclusion Criteria:
    • Compromised skin integrity in the perineal area (e.g., ulcers, open wounds, etc.).

    • Neurological impairment or psychiatric disorder preventing proper understanding of consent.

    • Unable to operate the PureWick system.

    • Unable to complete required questionnaires and diaries.

    • Investigator deems subject as unsuitable for enrollment.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Weill Cornell Medicine New York New York United States 10065

    Sponsors and Collaborators

    • Weill Medical College of Cornell University
    • Becton, Dickinson and Company

    Investigators

    • Principal Investigator: Bilal Chughtai, MD, Weill Medical College of Cornell University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Weill Medical College of Cornell University
    ClinicalTrials.gov Identifier:
    NCT05090722
    Other Study ID Numbers:
    • 21-05023603
    First Posted:
    Oct 25, 2021
    Last Update Posted:
    Dec 28, 2021
    Last Verified:
    Dec 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 28, 2021